The tau protein, historically recognized for its role in stabilizing microtubules, has recently emerged as a pivotal player in the pathogenesis of numerous neurodegenerative diseases. Intriguingly, despite tau’s extensive involvement in cellular processes—ranging from microtubule binding to interactions within various signaling pathways—the reduction or absence of tau has surprisingly subtle systemic effects. This observation challenges the long-held belief that tau-related neurodegenerative disease arises primarily from a loss of its physiological functions.
Conventional models have suggested a cascade where tau undergoes hyperphosphorylation during disease states, disrupting its interaction with microtubules, leading to their destabilization and eventual neuronal death. However, compelling evidence to support this linear progression remains insufficient. Studies reveal that in neurons, tau does not exert the robust microtubule stabilization once attributed to it, and knocking down tau fails to significantly compromise neuronal viability. This disconnect points toward alternative mechanisms driven by tau dysfunction.
A growing body of research champions the hypothesis that disease-modified tau acquires novel toxic properties, contributing directly to neurodegeneration. Experimental studies using neuronally differentiated cells have demonstrated that tau constructs mimicking the hyperphosphorylated state observed in pathological conditions induce cytotoxicity and activate apoptotic pathways, notably caspase-3, even in the absence of detectable aggregated tau filaments. This suggests that soluble, misfolded tau species, rather than large macroscopic aggregates, mediate cellular toxicity.
Corroborating this shift in understanding, multiple investigations highlight soluble tau oligomers as the principal toxic entities within tauopathies, exceeding the pathogenic impact of mature fibrillar aggregates. For instance, sonication-generated smaller tau oligomers incite heightened cytotoxic effects compared to stable fibrils. Moreover, in vivo models reveal that brain injections of tau oligomers perturb cognitive functions, synaptic integrity, and mitochondrial operations, underscoring their potency in driving disease phenotypes. This aligns with clinical observations where neuronal loss often exceeds the distribution of neurofibrillary tangles (NFTs), and the early formation of tau oligomers precedes the emergence of larger aggregates.
Compellingly, NFT-bearing neurons in some animal models maintain functional integrity, suggesting that neurofibrillary tangles may serve as sequestration reservoirs mitigating the deleterious effects of soluble tau species. Such protective aggregation presents a nuanced paradigm where fibrillary deposits could represent cellular defense mechanisms against soluble tau toxicity, reshaping therapeutic strategies targeting tau pathology.
Furthermore, the concept of tau-related toxicity extends beyond classical tauopathy syndromes, with protective effects observed following tau reduction in diverse models including amyloid-beta-induced pathology, autism spectrum disorders, epileptic encephalopathies, chronic stress, and persistent pain conditions. These findings emphasize tau’s broad involvement in neuronal pathology and implicate its dysregulation as a convergent pathological feature in multifactorial neurodegenerative and neuropsychiatric disorders.
Tau also appears intimately connected to adult hippocampal neurogenesis (AHN), a process increasingly implicated in cognitive health and disease. Tau knockout models reveal a dependence of AHN on tau function, with chronic stress exacerbating neurogenic deficits via tau-dependent pathways. Moreover, phosphorylated tau accumulation within inhibitory interneurons disrupts AHN, linking tau dysfunction to impaired hippocampal plasticity and memory deficits characteristic of early Alzheimer’s disease.
At the mechanistic level, the acquisition of tau’s toxic properties impinges on its primary microtubule-binding functions. Interestingly, tau’s interaction with microtubules exhibits dynamic “kiss-and-hop” kinetics critical for preserving microtubule-dependent axonal transport. Posttranslational modifications, such as caspase-3-mediated cleavage generating truncated forms like TauC3, increase tau’s microtubule residence time, hindering transport processes, and precipitating dendritic degeneration. Elevated TauC3 levels correlate with aging and Alzheimer’s disease, supporting a toxic gain-of-function model where altered tau-microtubule dynamics precipitate neuronal dysfunction.
Isoform balance also emerges as a key factor in tau toxicity. The adult human brain maintains equimolar levels of 3-repeat (3R) and 4-repeat (4R) tau isoforms, with deviations linked to tauopathies. Disruption of the 3R/4R equilibrium, stemming from aberrant exon 10 splicing, impairs axonal transport and exacerbates pathological tau accumulation, reinforcing isoform ratio as a critical determinant in disease progression and a potential therapeutic target.
Beyond microtubules, tau’s interactions within synaptic and signaling domains contribute substantially to its pathogenic profile. Tau modulates postsynaptic localization of the Src kinase Fyn, influencing amyloid-beta toxicity, while aberrant tau association with synaptic vesicles undermines synaptic function. Additionally, tau oligomers induce mitochondrial dysfunction, further compromising neuronal energy homeostasis. Hyperphosphorylated tau has been implicated in stabilizing β-catenin, which intriguingly can exert anti-apoptotic effects, indicating tau’s multifaceted role in neuronal survival and death pathways.
Emerging evidence delineates how pathologically altered tau propagates toxicity beyond individual neurons. Tau species can spread via non-traditional secretion mechanisms—direct translocation across the plasma membrane, vesicle-mediated release through exosomes and ectosomes, or via tunneling nanotubes—facilitating prion-like templated misfolding in recipient cells. This intercellular transfer underpins the stereotypical progression patterns observed in tauopathies as initially mapped out in Braak staging and reflects the strain-specific structural heterogeneity among tau aggregates.
Overall, the evolving comprehension of tau pathology underscores a paradigm shift from a simplistic loss-of-function framework to a complex gain-of-toxic-function model. This encompasses not only intracellular tau oligomer toxicity and microtubule disruptions but also nuanced synaptic and signaling perturbations as well as prion-like propagation mechanisms. These insights compel a re-evaluation of therapeutic strategies targeting tau, advocating for approaches that modulate soluble tau species and isoform balance, interfere with pathological posttranslational modifications, and inhibit tau propagation routes to mitigate neurodegeneration effectively.
This comprehensive understanding of tau’s multifaceted roles in neuronal physiology and pathology fuels hope for innovative interventions addressing the most pernicious neurodegenerative disorders. As research continues unraveling tau’s intricate biology, the challenge lies in translating these mechanistic insights into clinical applications capable of halting or reversing the devastating cognitive decline afflicting millions worldwide.
Subject of Research: The multifaceted role of tau protein in neuronal function and neurodegenerative disease mechanisms.
Article Title: Beyond microtubule regulation: the multifaceted roles of tau in neuronal function and dysfunction.
Article References:
Bakota, L., Tulva, K., Trushina, N.I. et al. Beyond microtubule regulation: the multifaceted roles of tau in neuronal function and dysfunction. Transl Psychiatry 16, 223 (2026). https://doi.org/10.1038/s41398-026-03947-1
Image Credits: AI Generated
DOI: 31 March 2026
Keywords: tau protein, neurodegeneration, tauopathies, microtubule interaction, tau oligomers, Alzheimer’s disease, neuronal toxicity, tau isoforms, tau propagation, neurogenesis, caspase-3 cleavage, synaptic dysfunction, prion-like mechanisms
